Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NICER: Neoadjuvant Atezolizumab + CAPOX for pMMR Colon Cancer
NCT05870800Phase 2Recruiting
- Sponsor
- Baylor College of Medicine
- Start
- Jun 2025
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in colon cancer, sponsored by Baylor College of Medicine. Primary endpoint: Rate of tumor regression grade 1 (<10% viable cancer cells). Started Jun 2025; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT05870800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05870800.